Livzon Group released its 2026 half-year report, showing first-half net profit attributable to the parent of 932 million yuan, down 27.2% year on year. Operating revenue was 5.0 billion yuan, down 20.3% year on year. Net profit attributable to the parent excluding non-recurring items was 890 million yuan, down 29.3% year on year. Net operating cash flow was 1.763 billion yuan, up 4.5% year on year. Second-quarter operating revenue was 2.13 billion yuan, down 31.1% year on year, and net profit attributable to the parent was 355 million yuan, down 44.9% year on year. The company said sales revenue from its chemical preparations business fell 25.33% due to medical insurance price cuts and national volume-based procurement. Sales revenue from traditional Chinese medicine preparations and other business segments fell 34.83%, mainly because the incidence of influenza and respiratory diseases declined in the first quarter, reducing demand for related products.
Livzon Pharmaceutical Group IncFirst-half net profit fell 27.2% and revenue dropped 20.3% due to price cuts and procurement.
